Long-term experience with GH replacement therapy: efficacy and safety
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Demonstration of the long-term efficacy of GH replacement in GH-deficient adults has depended on a combination of single-centre studies and data from large multinational databases, which, by virtue of their size, are likely to detect rare adverse events and also permit analysis of mortality rates. The Pharmacia International Metabolic Surveillance (KIMS) study (a pharmacoepidemiological survey of the safety and efficacy of GH replacement in adults, sponsored by Pharmacia) is currently the largest database, with information on over 8000 patients from a total of 27 countries. Abundant epidemiological evidence confirms that hypopituitarism is associated with premature mortality, with an increase in cardiovascular and cerebrovascular disease as a primary underlying cause. Central adiposity, hyperlipidaemia, insulin resistance, and diabetes mellitus are common in adults with hypopituitarism. GH replacement is associated with improvements in central fat mass and mean reductions in serum total and low-density lipoprotein cholesterol which may be additive to those achieved with hydroxymethylglutaryl-coenzyme A reductase inhibitors. These beneficial effects are maintained for at least 2 Years after initiation of therapy, as are reductions in central adiposity, with similar benefits seen in men and women when the GH dose is titrated to achieve a serum IGF-I between the median and the upper end of the age-related reference range. Fasting plasma glucose and glycated haemoglobin increase, usually within the reference range, during prolonged GH replacement, but do not tend to rise further above baseline in subjects with pre-existing impaired glucose tolerance. Bone remodelling increases during GH replacement therapy, but indices tend to return to baseline within 5 Years of commencing treatment. Bone mineral density increases in men whereas, in women, improvement is limited to stabilisation of bone density. Data from the KIMS study demonstrate that prolonged GH replacement is associated with a reduction in the number of patients requiring assistance with daily living and a significant reduction in sick leave and hospital admissions. GH replacement therapy improves psychological well-being, particularly in those patients with the greatest deficit prior to treatment, with improvement maintained beyond 6 Months of therapy and sustained during long-term follow-up. Data from the KIMS population show that there is no increase in the overall occurrence of de novo neoplasia or the rate of regrowth of primary pituitary tumours. There is an apparent increase in intracranial neoplasia, which may be an artefact of comparing a surveillance population with general population data. Unlike mortality in untreated hypopituitary GH-deficient patients, mortality in the KIMS study is currently similar to that predicted for the normal population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
The effect of hypopituitarism on life expectancy.
Bates, A. S., Van't Hoff, W., Jones, P. J., & Clayton, R. N. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772595 · Cited by 475
The growth hormone deficiency syndrome in adults
Cuneo, R. C., Salomon, F., McGauley, G. A., & Sönksen, P. H. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02347.x · Cited by 375
Wüster, C., Abs, R., Bengtsson, B.-Å., Bennmarker, H., Feldt-Rasmussen, U., Hernberg-Ståhl, E., Monson, J. P., Westberg, B., & Wilton, P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.398 · Cited by 267
Self-citationDrake, W. M., Rodríguez‐Arnao, J., Weaver, J. U., James, I. T., Coyte, D., Spector, T. D., Besser, G. M., & Monson, J. P. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01246.x · Cited by 76
Self-citationCost of illness in adult patients with hypopituitarism
Ehrnborg, C., Hakkaart-Van Roijen, L., Jonsson, B., Rutten, F. F. H., Bengtsson, B.-?., & Ros??n, T. (2000) · PharmacoEconomics · doi:10.2165/00019053-200017060-00008 · Cited by 47
Cited by
Schneider, H. J., Kreitschmann-Andermahr, I., Ghigo, E., Stalla, G. K., & Agha, A. (2007) · JAMA · doi:10.1001/jama.298.12.1429 · Cited by 549
“Growth hormone replacement is indicated for adults with severe growth hormone deficiency(60) and its salutary effects are well documented.(61) In the presence of biochemical and clinical evidence of persistent severe growth hormone deficiency and additional pituitary hormone deficiencies, growth hormone substitution s…”
BackgroundAnterior Pituitary Dysfunction in Survivors of Traumatic Brain Injury
Agha, A., Rogers, B., Sherlock, M., O’Kelly, P., Tormey, W., Phillips, J., & Thompson, C. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0511 · Cited by 390
Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00005 · Cited by 370
“Although GH therapy has been shown to improve clinical outcomes (20–22) and possibly decrease death (23) in longitudinal studies of adults who are GH-deficient, we find little evidence of clinical benefit of GH therapy in the healthy elderly.”
BackgroundNeuroendocrine dysfunction in the acute phase of traumatic brain injury
Agha, A., Rogers, B., Mylotte, D., Taleb, F., Tormey, W., Phillips, J., & Thompson, C. J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02023.x · Cited by 313
“Beneficial effects of GH treatment in GH-deficient adults have been clearly documented (Monson, 2003), although there are no trial data reporting on the use of GH treatment in the rehabilitation phase of TBI.”
BackgroundSOCS2 negatively regulates growth hormone action in vitro and in vivo
Greenhalgh, C. J., Rico-Bautista, E., Lorentzon, M., Thaus, A. L., Morgan, P. O., Willson, T. A., Zervoudakis, P., Metcalf, D., Street, I., Nicola, N. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522710 · Cited by 258
Metadata
- Authors
- Monson, J.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-04-01
- Volume
- 148 Suppl 2
- Pages
- S9-14
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2132877559
- Cited by
- 120
- References
- 7
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term experience with GH replacement therapy: efficacy and safety. https://app.cochat.ai/papers/10.1530/eje.0.148s009
- The paper
- Monson, J. (2003). Long-term experience with GH replacement therapy: efficacy and safety. European Journal of Endocrinology. https://doi.org/10.1530/eje.0.148s009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.